Cat Allergy Shots: The Evidence-Based Guide to SCIT
Cat allergy shots (SCIT) are supported by the strongest evidence base of any companion-animal immunotherapy, with real-world studies reporting 85-90% improvement rates. Fel d 1 — a secretoglobin found in 99.9% of US homes — is the dominant target sensitizing 90-96% of cat-allergic patients. FDA-standardized cat-hair extract (10,000 BAU/mL) enables precise dosing for patients who choose to keep their cat.
About Curex’s SCIT program
Curex’s at-home allergy shots (SCIT) are coming soon and focus on the most common environmental allergens:
- • Pollens — tree, grass, weed & ragweed
- • Pet dander — cat & dog
- • Dust mites
- • Molds — Alternaria & mold mix
Catis covered here for general education and may not be part of Curex’s current treatment set. Join the waitlist and our care team will help confirm your options.
Cat Allergy Immunotherapy: How It Works
Allergy immunotherapy is the only long-term treatment that re-trains the immune system to stop overreacting to cat — rather than just masking symptoms with antihistamines or steroids. By gradually exposing the body to controlled doses of cat allergen, immunotherapy shifts the underlying allergic response and produces relief that often outlasts treatment by 7–10 years.
There are two evidence-based forms of cat immunotherapy used today, both built on the same desensitization principle but delivered very differently.
of sustained relief after a complete immunotherapy course — the only allergy treatment with proven long-term effect after stopping.
Allergy Shots (SCIT)
Weekly injections of cat extract in a clinic, escalating over 3–6 months until a maintenance dose is reached. Continued monthly for 3–5 years. Longest clinical track record for cat allergy.
- Strongest evidence base for severe and polysensitized patients
- Covered by most insurance plans
- Requires 50–100+ in-person clinic visits across the full course
- Or at home with no clinic visits— Curex’s Virtual Shot Room model delivers the same SCIT program with live video supervision by trained Curex clinical staff for the first injection from each new vial or concentration and restarts after gaps or reactions.
Allergy Drops / Tablets (SLIT)
Daily drops or dissolvable tablets containing cat extract, held under the tongue at home. Same desensitization principle, delivered without injections. WHO-recognized as an effective form of allergy immunotherapy since 2001.
- Taken at home — no weekly clinic trips, no needles
- Lower systemic reaction rate than allergy shots
- Curex offers prescription cat immunotherapy drops with allergist oversight
The rest of this page goes deep on allergen-specific immunotherapy with shots — protocol, efficacy data, side effects, and cost. If you’d rather skip the clinic and treat cat allergy with at-home drops, see how Curex sublingual immunotherapy compares below.
What is Cat?
The biology, taxonomy, and clinical fingerprint of Cat — the foundation of how SCIT targets it.
Fel d 1 detected in 99.9% of US homes including cat-free homes at ~1.0 μg/g; airborne respirable particles remain suspended up to two weeks (Custovic et al., Thorax 1998).
- Scientific name
- Felis catus
- Family
- FelidaeCat family
- Type
- Indoor animal dander allergen
- Native to
- Domesticated worldwide; wild progenitor Felis silvestris originates in Middle East and North Africa
- Allergen proteins
- Fel d 1 (major) — 35-38 kDa tetrameric secretoglobin; the only major allergen in any species where a secretoglobin, not a lipocalin, dominatesFel d 2 — serum albumin, 69 kDa; drives pork-cat syndrome via Sus s 1 cross-reactivityFel d 3 — cystatin, 11 kDa; limited commercial assay availabilityFel d 4 — lipocalin, 22 kDa; 32-63% sensitization; cross-reacts with Equ c 1 (horse) and Can f 6 (dog)Fel d 7 — lipocalin, 17.5 kDa; 62% identity with dog Can f 1Fel d 8 — latherin-like protein, 24 kDa; limited characterization
- Particle size
- <4.7 μm (respirable airborne fraction, ~23%); >9 μm (larger particle fraction, ~49%)
- Avoidance difficulty
- Nearly impossible
How Cat Allergy Presents
Symptoms by body system — useful for distinguishing Cat sensitivity from overlapping allergies and infections.
Respiratory
- Nasal congestion, rhinorrhea, and sneezing within minutes of cat contact
- Coughing and wheezing triggered by even brief indirect exposure
- Asthma exacerbations — cat allergen drives >500,000 US emergency visits annually (Satyaraj et al., 2019)
- Persistent perennial rhinitis even in cat-free environments via transported allergen
- Bronchospasm in sensitized patients entering rooms occupied by cats hours earlier
Ocular
- Bilateral conjunctivitis with tearing and redness on cat exposure
- Intense eye itching (pruritus) often more prominent than nasal symptoms
- Periorbital swelling in moderate-to-severe reactions
- Eyelid angioedema in highly sensitized individuals
Dermal
- Contact urticaria at scratch or bite sites from saliva
- Hive-like wheals following direct cat contact, especially on face and arms
- Flare of pre-existing eczema (atopic dermatitis) with repeated cat exposure
- Localized angioedema after direct saliva contact
Systemic
- Fatigue and cognitive fog from chronic perennial low-grade inflammation
- Sleep disruption secondary to nocturnal nasal obstruction from bedroom exposure
- Rarely, anaphylaxis following unusually high allergen challenges (e.g., entering a heavily contaminated space after a prolonged absence)
- Increased susceptibility to secondary sinus and middle-ear infections
Cat allergy has the immunotherapy evidence story we trust most — and the most compelling clinical reality: the cat is non-negotiable for most patients. The interesting question is rarely 'will SCIT work?' but 'is this patient primarily allergic to Fel d 1, or are they sensitized to Fel d 4 — the lipocalin that cross-reacts with horse and dog?' One component blood draw usually answers that before we write a single prescription.
Where Cat Triggers Year-Round
Cat is a perennial trigger — exposure is constant for sensitized patients. Geographic intensity still varies by climate.
12-Month Intensity
Year-roundPerennial: cat allergen is present year-round. Indoor levels peak in winter when ventilation is reduced and time spent indoors increases.· 365 days per year; Fel d 1 persists 20+ weeks after cat removal and contaminates schools, offices, and public transport via clothing transfer.
US Exposure Map
20 high-intensity statesExposure intensity by state (text version)
- ME:
- Moderate
- VT:
- Low
- NH:
- Low
- WA:
- High
- MT:
- Low
- ND:
- Low
- MN:
- Moderate
- WI:
- Moderate
- MI:
- High
- NY:
- High
- MA:
- High
- OR:
- Moderate
- ID:
- Moderate
- WY:
- Low
- SD:
- Low
- IA:
- Moderate
- IL:
- High
- IN:
- High
- OH:
- High
- PA:
- High
- NJ:
- High
- CT:
- Moderate
- RI:
- Low
- CA:
- High
- NV:
- Moderate
- UT:
- Moderate
- CO:
- High
- NE:
- Moderate
- MO:
- High
- KY:
- Moderate
- WV:
- Moderate
- VA:
- High
- MD:
- High
- DE:
- Low
- AZ:
- High
- NM:
- Moderate
- KS:
- Moderate
- AR:
- Moderate
- TN:
- High
- NC:
- High
- SC:
- Moderate
- OK:
- Moderate
- LA:
- None
- MS:
- Moderate
- AL:
- Moderate
- GA:
- High
- TX:
- High
- FL:
- High
- AK:
- Low
- HI:
- Moderate
What Cat Cross-Reacts With
Patients sensitized to one allergen often react to others sharing similar proteins. This map shows the documented molecular overlaps.
Fel d 1 is species-specific with no clinically significant cross-reactivity, but cat's minor allergens Fel d 2 (serum albumin) and Fel d 4 (lipocalin) drive extensive cross-mammalian reactivity — this is clinically critical for identifying the true primary sensitizer.
Pork-cat syndrome: Fel d 2 ↔ Sus s 1 serum albumin; cat-sensitized patients may react to pork meat
Fel d 4 ↔ Equ c 1 lipocalin (~67% identity) — the lipocalin triad connecting cat, dog, and horse
Fel d 4 ↔ Can f 6 lipocalin (67% identity); Fel d 7 ↔ Can f 1 (62% identity); Fel d 2 ↔ Can f 3 albumin
Is SCIT Right for Your Cat Allergy?
Answer five questions to assess whether cat allergy shots are likely to be a strong option for your situation.
How severe are your cat allergy symptoms on a typical day you're exposed?
The Cat SCIT Protocol
Cat SCIT uses FDA-standardized cat-hair extract (10,000 BAU/mL) — the only mammalian dander allergen with this regulatory designation — enabling precise, reproducible dosing across clinics.
Injections begin at a highly diluted concentration and increase incrementally each visit. Patients wait 30 minutes in the clinic after each injection for observation. Component-resolved diagnostics (Fel d 1 vs Fel d 4 vs Fel d 2) should ideally be completed before starting to confirm primary sensitization.
Once the maintenance dose is reached, injection frequency decreases to on a schedule individualized by your allergist. Most patients notice meaningful symptom improvement within 6-12 months of starting. For patients who also have comorbid asthma, stable asthma control (FEV1 >70% predicted) should be confirmed before each maintenance injection.
After a complete 3-5 year course, many patients maintain meaningful symptom reduction for years beyond the last injection. Your allergist will assess whether sustained remission supports discontinuation or whether continued maintenance is warranted based on your exposure level and symptom burden.
Extract Concentration Ladder
You progress through each vial during build-up. Concentration increases ~10x per step.
What the Research Shows for Cat SCIT
Cat SCIT has three published double-blind placebo-controlled RCTs and robust real-world cohort data — the strongest evidence base of any companion-animal immunotherapy.
- Real-world symptom improvement87%PMC6125099 meta-analysis of cat SCIT cohorts; N=multiple cohorts
- Symptom score reduction (SCIT, 1 year)59%Álvarez-Cuesta et al., Allergy 2007; 62:810-817; N=50 (SLIT arm for comparison)
- NNT: 3 for preventing asthma deterioration75%Abramson et al., Cochrane Review 2003; 88 trials, N=3,459 patients
- Reduction in exacerbations (omalizumab as adjunct)50%Massanari et al., Allergy Asthma Proc 2009; N=811 cat-sensitive asthmatics
The convergence of three double-blind RCTs (Ohman 1984, Álvarez-Cuesta 1994, Varney 1997), a Cochrane meta-analysis covering 3,459 patients, and real-world 85-90% improvement data establishes cat SCIT as the best-evidenced companion-animal immunotherapy. Patients with asthma comorbidity show the most clinically meaningful gains. The FDA-standardized extract (10,000 BAU/mL) is a key driver of these reproducible outcomes.
Ready to skip the surprise bills?
At-home allergy shots (SCIT) are designed by board-certified allergists. See the listed SCIT plan rate in our pricing record and request a quote for eligibility, initiation and total care costs.
- MD-ledBoard-certified allergists
- QuoteTotal care estimate
- 50K+Patients treated
- HSA/FSAEligible
Cat SCIT Side Effects
Cat SCIT with FDA-standardized extract has a well-characterized safety profile. Systemic reaction rates are ~0.1-0.2% per injection — lower than for many non-standardized allergens — and patients with asthma must have stable baseline lung function before each injection.
Local reactions
4 documented| Reaction | Rate | Severity |
|---|---|---|
Injection-site swelling Wheal and flare at injection site; typically resolves within 30-60 minutes | Rate 30-50% | Mild |
Injection-site itching Pruritus at the injection site; cold compresses can help | Rate 20-40% | Mild |
Large local reaction (>25 mm wheal) Significant swelling persisting >24 hours; allergist may adjust dose upward more slowly | Rate 5-10% | Moderate |
Delayed local reaction (4-8 hours post-injection) | Rate 5-15% | Mild |
Systemic reactions
4 documented| Reaction | Rate | Severity |
|---|---|---|
Generalized urticaria Hives beyond the injection area; requires prompt treatment and dose adjustment | Rate 0.1-0.5% per injection | Moderate |
Rhinitis/conjunctivitis flare Nasal or eye symptoms within 30 minutes; managed with antihistamine | Rate 0.2-0.5% | Mild |
Mild bronchospasm More likely in patients with poorly controlled baseline asthma | Rate 0.1-0.2% | Moderate |
Anaphylaxis Rate: 1 confirmed fatality per 23.3 million injection visits (ACAAI/AAAAI survey 2008-2012); a prescribed epinephrine auto-injector is confirmed on hand at the injection location for at-home Curex SCIT | Rate <0.01% per injection | Severe |
Traditionally SCIT was given only in a clinic, but for eligible patients Curex makes safe at-home self-administration possible: a personalized serum sterile-compounded to USP <797> and lot-tested, a prescribed epinephrine auto-injector confirmed on hand before the first injection, and the first injection from each new vial or concentration supervised live in the Virtual Shot Room by trained Curex clinical staff. The per-injection anaphylaxis risk is extremely low with standardized extract; reactions typically begin within ~30 minutes, so a brief post-injection self-observation is advised, and fatalities are exceedingly rare in the modern era of supervised SCIT.
SCIT vs Alternatives for Cat
Cat-allergic patients who keep their cat have four evidence-based options: SCIT (85-90% real-world improvement, Alvarez-Cuesta 1994 and Varney 1997 RCTs), at-home SLIT drops (59% symptom reduction per Álvarez-Cuesta 2007), avoidance via rehoming (complete but rarely chosen), and daily medications (antihistamines plus nasal corticosteroids — partial relief only).
| Criterion | SCITBest | SLIT | Avoidance | Medications |
|---|---|---|---|---|
| Effectiveness | 85-90% improvement | 59% symptom reduction (Álvarez-Cuesta 2007) | Complete if successful | Partial relief; symptoms return when stopped |
| 5-yr cost | $3,500-$10,000 | Varies by provider | $0 | $500-$2,000/yr |
| Duration | 3-5 years | 3-5 years | Permanent | Indefinite (no end) |
| Convenience | Self-administered weekly at home with Curex (build-up) | Daily drops at home | Requires rehoming cat | Daily pills/sprays |
| Safety | Very safe; Curex confirms prescribed epinephrine on hand and supervises the first injection from each new vial or concentration live in the Virtual Shot Room | Very safe; no clinic required | No side effects | Generally safe long-term |
| Lasting effect | Years of remission post-course | Ongoing benefit while continuing | Permanent if strict | No lasting effect after stopping |
SCITBest
SLIT
Avoidance
Medications
For cat-allergic patients who keep their cat, SCIT offers the best evidence for lasting, meaningful symptom reduction. Curex delivers that same cat immunotherapy as a weekly shot you give yourself at home with pricing confirmed in a current program quote — a personalized serum sterile-compounded to USP <797>, the first injection from each new vial or concentration supervised live in the Virtual Shot Room by trained Curex clinical staff, with a prescribed epinephrine auto-injector confirmed on hand. It removes the weekly clinic trips of traditional build-up for eligible patients.
What Cat SCIT Actually Costs
Most major US health insurers cover cat SCIT under standard allergy benefits when prescribed by a board-certified allergist. The FDA-standardized cat-hair extract designation means coverage decisions are generally well-established. Out-of-pocket costs depend on deductible, co-insurance, and whether office-visit charges are bundled. Curex at-home IgE testing identifies specific cat sensitization before allergist consultations, eliminating the need for an initial skin-test visit.
Cost range varies by deductible, co-insurance, and clinic.
Verify these codes with your insurer to confirm coverage.
See the listed Environmental Allergy Shots Plan rate, commercial terms dated 2026-10-12; consultations are included without copay. Confirm availability, eligibility, other included services, testing, any in-person care, insurance responsibility and billing cadence in your written quote before enrolling.
Join the waitlistStop guessing about your cat allergy. Get a plan.
Take Curex’s 3-minute allergy quiz. A board-certified allergist will review your symptoms and recommend the right immunotherapy path for you — shots or drops.
Free quiz · Board-certified allergists · 50,000+ patients treated · HSA/FSA eligible
Cat SCIT — Frequently Asked
Quick answers to the questions patients ask most before starting treatment.
Most patients notice meaningful improvement in symptoms within 6-12 months of starting cat SCIT. Clinical improvements typically begin during the build-up phase, with the most significant benefits emerging after reaching the maintenance dose. In real-world practice, 85-90% of patients who complete a full course report substantial improvement. However, the immune tolerance that SCIT builds takes time — expecting complete relief within the first few injections is not realistic. A board-certified allergist can confirm whether component-resolved diagnostics (Fel d 1 vs Fel d 4) suggest a patient is likely to be a strong responder before starting.
Yes, antihistamines are generally compatible with cat SCIT and are often continued during the build-up phase to reduce the risk of local injection-site reactions. Your allergist may recommend taking an antihistamine before each injection visit as a pre-medication strategy. Antihistamines do not appear to blunt the immune-tolerance response that SCIT induces. Nasal corticosteroid sprays can also be continued alongside SCIT. As symptoms improve over the maintenance phase, many patients find they can reduce or discontinue antihistamines. Always confirm any medication adjustments with your allergist.
No — this is a widely circulated myth with no rigorous peer-reviewed support. Vredegoor et al. (JACI 2012) found no consistent breed-based difference in Fel d 1 production. Kelly et al. (JACI 2018) confirmed that Fel d 1 levels in cat fur were unrelated to breed, sex, or coat color. Even hairless Sphynx cats produce Fel d 1 (Hilger et al., 2024). Siberian breeders cite data from a non-peer-reviewed breeder organization suggesting ~50% of Siberians have lower Fel d 1, but only ~15% of those cats reached levels low enough for severely allergic patients. An accompanying editorial in JACI 2012 by Lockey was titled 'The myth of hypoallergenic dogs (and cats).' Individual cats vary enormously in Fel d 1 production — up to 80-fold between individuals — but this is not reliably predicted by breed.
This depends on which allergen is the primary driver. Cat, dog, and horse share the lipocalin triad: Fel d 4 (cat), Can f 6 (dog), and Equ c 1 (horse) cross-react with 55-67% sequence identity, meaning you may be primarily sensitized to one species' lipocalin and cross-reacting to the others. Component-resolved diagnostics — measuring Fel d 1, Fel d 4, Can f 1, Can f 6, and Equ c 1 separately — can identify the primary sensitizer. If your cat allergy is driven by Fel d 1 (cat-specific secretoglobin), cat SCIT is the targeted approach; if Fel d 4 is dominant, and you have more horse exposure, horse-directed immunotherapy might be more effective.
Missing occasional injections during the maintenance phase typically requires a minor dose reduction at your next visit — standard SCIT protocols have defined adjustment schedules based on the time elapsed since the last injection (usually 0-6 weeks: same dose; 6-8 weeks: slight reduction; >8 weeks: larger reduction). During the build-up phase, missed visits may require starting from an earlier concentration to ensure safety. Never skip the 30-minute post-injection observation period. Your allergist will provide a written schedule and guidance for handling missed appointments. Consistent adherence through the full 3-5 year course is the strongest predictor of lasting benefit.
Most major US health insurers — including Blue Cross Blue Shield, Aetna, Cigna, and UnitedHealthcare — cover cat SCIT under standard allergy benefits when prescribed by a board-certified allergist. Coverage typically includes both the extract preparation (CPT 95165) and the injection visits (CPT 95115 or 95117). Because cat-hair extract is FDA-standardized (10,000 BAU/mL), coverage decisions tend to be clearer and more favorable than for non-standardized extracts. Prior authorization may be required. Your out-of-pocket cost depends on your deductible, co-insurance percentage, and whether the extract preparation and office visits are billed separately. Confirming coverage before starting is recommended.
Pork-cat syndrome occurs because sensitization to cat serum albumin (Fel d 2) generates cross-reactive IgE that recognizes porcine serum albumin (Sus s 1) in pork. In theory, reducing cat-specific IgE via SCIT could secondarily reduce Sus s 1 cross-reactivity, but direct clinical evidence for this secondary benefit is limited and inconsistent. Cat SCIT primarily targets Fel d 1, not Fel d 2 (albumin). Patients with pork-cat syndrome should continue to avoid lightly cooked pork regardless of SCIT status. A board-certified allergist can perform serum-albumin IgE testing (Fel d 2, Sus s 1) and monitor food tolerance over the course of immunotherapy, but pork reintroduction should only be attempted under supervised food challenge conditions.
Yes — cat SCIT is well-established in pediatric patients and is generally considered safe for children 5 years and older who can cooperate with the injection and observation protocol. Multiple clinical studies include pediatric populations. A large safety study of self-administered allergen immunotherapy found that across 23,614 patients giving 2,021,600 injections, the systemic reaction rate was just 0.16% per patient with no fatalities — lower than the 3%–14% typically seen with office-based shots. Children with comorbid asthma must have well-controlled baseline lung function (typically FEV1 >70% predicted) before starting and at each maintenance visit. The Cochrane meta-analysis (Abramson et al. 2003) covering 3,459 patients included pediatric populations and found significant benefit for preventing asthma deterioration (NNT 3). A board-certified pediatric allergist can assess readiness and design the appropriate build-up schedule for a child's weight and clinical profile.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.
Questions about Curex itself?
Straight answers about the company, the evidence, what patients report, and what it costs — including the parts that are not flattering.